BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Merck & Co., Inc. (MRK) Hid Fosamax's Bone-Weakening Risks, Lawyer Contends


3/13/2013 7:44:15 AM

Merck & Co. (MRK) officials hid the risks that its Fosamax osteoporosis drug could weaken bones and lead to femur fractures, a lawyer told a New Jersey jury in the first case raising such claims to come to trial. Merck researchers ignored signs that extended use of drugs known as bisphosphonates, such as Fosamax, caused femurs to deteriorate in patients such as Christina Su, said Karen Menzies, one of Su’s lawyers, today in opening statements of the trial of the woman’s claims over the drug. Merck officials have said in securities filings that they face more than 3,300 lawsuits alleging Fosamax caused such fractures. To ramp up Fosamax sales, Merck officials “disregarded safety risks” and pushed the drug for women who weren’t suffering from osteoporosis, Menzies said. The trial in state court in Atlantic City comes more than a month after Whitehouse Station, New Jersey-based Merck said it expected profit to decline this year because of generic competition to its top-selling drug Singulair and research setbacks that slowed efforts to get new medicines to market. Merck officials contend Fosamax didn’t cause the 67-year- old Su’s femur fracture and the company properly warned doctors and patients about the drug’s risks. Christy Jones, a lawyer for Merck, told jurors today that Menzies had no evidence to support claims Merck turned a blind eye to Fosamax’s safety problems. The U.S. Food and Drug Administration repeatedly approved the medicine as safe and effective for women worried about bone-density loss, Jones said. ‘Fragility Fractures:’ Merck’s lawyer also said Su’s medical records showed her bones were strengthened by her Fosamax use and that she fell into the category of women who were at risk for “fragility fractures.” Medical evidence that will be presented in the four-week trial will show Su “suffered the same kind of fracture” suffered by women who didn’t take Fosamax, Jones said in her opening statement.

Read at Bloomberg

Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES